标题:Efficacy and safety of Chinese herbal medicine for cough variant asthma: A network meta-analysis of randomized clinical trials
作者:Bai, Chenxiao; Wang, Liwen; Jiang, Di; Chen, Ou
作者机构:[Bai, Chenxiao; Wang, Liwen; Jiang, Di; Chen, Ou] Shandong Univ, Nursing Sch, ADD 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
通讯作者:Chen, O(chenou@sdu.edu.cn)
通讯作者地址:Chen, O (corresponding author), Shandong Univ, Nursing Sch, ADD 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China.
来源:EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
出版年:2020
卷:34
DOI:10.1016/j.eujim.2019.101028
关键词:Cough variant asthma; Chinese herbal medicine; Montelukast; Randomized; controlled trials; Safety; Efficacy; Network meta-analysis
摘要:Introduction: Cough variant asthma (CVA) can lead to chronic cough or typical asthma. Though western medications have shown benefit, many patients do not achieve long term effects. Chinese herbal medicine (CHM) has been used for patients with CVA, however its benefit is unclear. This review aimed to evaluate the efficacy of different CHM for patients with CVA using network meta-analysis.; Methods: Embase, Cochrane Library, PubMed, Web of Science, CNKI and WanFang databases were searched to identify randomized controlled trials (RCTs) that compared the efficacy of CHM with Montelukast (western medicine). Studies selection, data extraction, and quality evaluation were independently conducted by two reviewers. Network meta-analysis was performed to rank different therapies according to efficacy and adverse rates.; Results: A total of 25 RCTs involving 2635 participants were included in the study. The study indicated that compared with Montelukast, the efficacy rate of CHM was significantly higher (Odd ratio (OR) = 4.13; 95% credible intervals (CI): 3.29-5.20). Only 8 RCTs reported the adverse reactions. The study suggested fewer adverse effects of CHM (OR = 0.26; 95% CI: 0.16-0.43) when compared with Montelukast. In the network meta-analysis, Suhuang Zhike Capsule (SZC) + Montelukast, Xiaoqinglong Decoction (XQLD) + Montelukast, Zhisousan + Montelukast and ephedra soup + Montelukast were most likely to take effect in CVA patients, while SZC + Montelukast and Montelukast were more likely to have adverse effects.; Conclusions: Compared with Montelukast, CHMs were more effective and had less adverse effects in the treatment of CVA.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079124283&doi=10.1016%2fj.eujim.2019.101028&partnerID=40&md5=b838095d72f87d0c15b997c846c508fc
TOP